Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline ResultsSeeking Alpha • 01/28/22
Checkpoint Therapeutics to Participate in the B. Riley Securities' Virtual Oncology ConferenceGlobeNewsWire • 01/25/22
Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell CarcinomaGlobeNewsWire • 01/25/22
Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung CancerGlobeNewsWire • 12/08/21
Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data ReadoutSeeking Alpha • 11/26/21
Checkpoint Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare ConferenceGlobeNewsWire • 09/22/21
Checkpoint Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare ConferenceGlobeNewsWire • 07/08/21
4 Biotech and Life Sciences Stocks Trading Under $10 With Gigantic Upside Potential24/7 Wall Street • 06/19/21
AEMD, CTEK, AEHL, AMSWA, CKPT, CLNE, SPI, ATOM, PUBM, IMH Stock Prices Gain IntradayPulse2 • 06/09/21
Lordstown, Morgan Stanley, ResMed and More Wednesday Afternoon Analyst Calls24/7 Wall Street • 06/09/21
Checkpoint Therapeutics Announces Completion of Enrollment in the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell CarcinomaGlobeNewsWire • 05/12/21
Checkpoint Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/06/21
Checkpoint Therapeutics Reports Full-Year 2020 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/09/21